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A B S T R A C TObjectives: To estimate the cost-effectiveness of trabectedin plus
pegylated liposomal doxorubicin (PLD) compared with PLD alone for
the treatment of patients with relapsed platinum-sensitive ovarian
cancer who are not expected to benefit from retreatment with
platinum-based therapies based on the final survival data published
in October 2012. Methods: A decision-analytic model estimated the
cost per quality-adjusted life-year (QALY) gained for trabectedin plus
PLD compared with PLD alone from the UK National Health Service
and Personal Social Services perspective over a lifetime horizon. Mean
progression-free survival and overall survival were calculated by using
parametric survival distributions adjusted for imbalances discovered
in the final survival data. Between-arm imbalances included the
platinum-free interval, cancer antigen 125 (CA-125), and Eastern
Cooperative Oncology Group performance score. Cost categories
included drug, administration, medical management, and treatment
of adverse events. Quality of life was measured by using the EuroQol
five-dimensional questionnaire. Uncertainty was addressed bysee front matter Copyright & 2013, International
r Inc.
.1016/j.jval.2013.01.011
g-group.com.
ondence to: Mark Fisher, 2 Cressex Road, High Wycdeterministic and probabilistic sensitivity analysis. Results: Over a
lifetime horizon, trabectedin plus PLD increased mean progression-
free survival by 3.0 months and overall survival by 9.7 months
compared with PLD alone. The additional cost and QALYs of trabecte-
din plus PLD were £18,476 and 0.49, resulting in an incremental cost-
effectiveness ratio of £38,026 per QALY. Sensitivity analyses showed
that results were sensitive to platinum-free interval adjustment and
the choice of survival distributions. Conclusions: The analysis esti-
mated a significant improvement in mean overall survival and
incremental cost per QALY compared with that calculated in the
original National Institute for Health and Clinical Excellence assess-
ment, which was based on immature survival data.
Keywords: cost-effectiveness analysis, decision analytic model,
ovarian cancer, trabectedin, UK.
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The optimal treatment for women with relapsed ovarian cancer
is evolving, and despite treatment advances, improvements in
ovarian cancer survival rates have been modest, with a median
survival after recurrence of just 2 years [1]. Patients with disease
relapsing more than 6 months after completion of a platinum
regimen are considered to have platinum-sensitive disease and
are generally offered a platinum agent or platinum combination
therapy [2]. Patients with longer relapse-free intervals are known
to respond better to another exposure to platinum-based regi-
mens. The relapse-free interval from which platinum exposure is
not required is also known as the platinum-free interval (PFI), and
is not to be confused with progression-free interval. One study
that investigated retreatment with platinum compounds found
PFI to be a significant predictor of response; 17% (6 of 35) of the
patients who relapsed before 18 months responded as compared
with 53% (10 of 19) who relapsed after 18 months (P ¼ 0.006) [3].
There is, however, a significant number of patients with
platinum-sensitive disease for whom retreatment withplatinum-based agents is not recommended. These include
patients developing toxicities, such as severe hypersensitivity
reactions or neurotoxicity, as well as patients with a shorter PFI
(o12 months) who are less likely to benefit from platinum
retreatment [4,5]. Furthermore, it is becoming clear from various
phase II and phase III clinical studies that the performance of
many nonplatinum chemotherapeutic agents is also influenced
by PFI [2] and for some patients with platinum-sensitive disease,
the use of nonplatinum-containing regimens is an alternative
treatment option. When nonplatinum treatment is planned,
single-agent pegylated liposomal doxorubicin (PLD) (Caelyx; Jans-
sen Biotech Inc., Horsham, PA) is usually used, and it has
demonstrated superiority over topotecan and paclitaxel [6,7]. In
the UK, current guidelines from the National Institute for Health
and Clinical Excellence (NICE) recommend single-agent PLD as an
option for women with partially platinum-sensitive disease and
women with platinum-sensitive disease who are allergic to
platinum-based compounds [8].
Trabectedin (Yondelis; PharmaMar, Madrid, Spain) is a marine-
derived antineoplastic agent first approved as a single-agentSociety for Pharmacoeconomics and Outcomes Research (ISPOR).
ombe, UK.
Fig. 1 – Distribution of platinum-free interval between the two arms. PLD, pegylated liposomal doxorubicin.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 5 0 7 – 5 1 6508therapy for patients with soft-tissue sarcoma after failure of
standard-of-care chemotherapies or who are unsuited to receive
these agents. Following promising results in preclinical studies and
as a single agent in phase II studies, a large randomized, multi-
center, phase III trial (OVA-301) evaluated the combination of
trabectedin plus PLD compared with PLD alone in patients with
relapsed ovarian cancer (n ¼ 672) and measured progression-free
survival (PFS) by independent radiology review as the primary end
point [9,10]. Patients included in the study had recurrent or
progressive disease, experienced one platinum-containing regimen
and were not expected to benefit, or were ineligible or not willing to
receive retreatment with platinum-based therapy. Patients were
stratified by Eastern Cooperative Oncology Group (ECOG) perform-
ance score (0–1 vs. 2) and platinum sensitivity of their disease
(sensitive: PFIZ 6 months vs. resistant: PFIo 6 months).
Trabectedin plus PLD significantly improved PFS compared
with PLD alone, and was associated with a 21% risk reduction of
progression (hazard ratio [HR] ¼ 0.79; 95% confidence interval [CI]
0.65–0.96; P ¼ 0.019; median PFS 7.3 vs. 5.8 months) and adequate
tolerability. In the platinum-sensitive stratum, the risk reduction
of disease progression was 27% (HR ¼ 0.73; 95% CI 0.56–0.95; P ¼
0.017; median PFS 9.2 vs. 7.5 months). An interim analysis of
overall survival (OS) was conducted with 419 events (vs. 520
required for the final analysis of OS [9]) on request from the
European Medicines Agency and showed a 15% reduction in the
risk of death with the combination (HR ¼ 0.85; P ¼ 0.092; median
OS 22.4 vs. 19.5 months). Based on the PFS together with a
positive trend in OS and a positive benefit/risk balance, the
European Medicines Agency granted marketing authorization
for trabectedin plus PLD for the treatment of patients with
relapsed platinum-sensitive ovarian cancer in October 2009 [11].
A NICE submission was conducted for the platinum-sensitive
population on the basis of the interim analysis during 2010 and it
was concluded in April 2011 that there was not enough evidence
to recommend trabectedin plus PLD [12]. This was primarily
because the incremental cost-effectiveness ratio (ICER) for trabec-
tedin plus PLD could be higher than £95,000 per quality-adjusted
life-year (QALY) gained compared with PLD alone. It was, however,
acknowledged that the submission was based on immature data
because the prespecified number of events for final analysis of OS
(520 events) had not been reached [9,12]. In addition, trabectedinplus PLD could not be compared with retreatment with platinum-
based compounds, which is standard clinical practice in the
platinum-sensitive population, and therefore comparing trabec-
tedin plus PLD with PLD alone was considered clinically relevant
only for circumstances in which platinum-based regimens would
be unsuitable for platinum-sensitive patients [12].
In March 2011, 522 (77.7%) death events had occurred and the
final protocol-specified analysis of OS was published in 2012 [10].
The final analysis reinforced the stronger trend for longer survival
in patients treated with trabectedin plus PLD. Among the 430
platinum-sensitive patients, 316 (73.5%) death events were
observed and there was a 17% reduction in the risk of death with
the combination (HR ¼ 0.83; 95% CI 0.67–1.04; P ¼ 0.106; median OS
27.0 vs. 24.1 months). In addition, this analysis showed an
unanticipated, yet significant, imbalance in the PFI favoring the
PLD arm: in the entire trial population, the mean PFI for the
trabectedin plus PLD arm was 10.6 months versus 13.3 months in
the PLD arm, P ¼ 0.009 (Fig. 1) [10]. When prognostic factors
(including PFI) were included in the Cox regression model, the
treatment with trabectedin plus PLD resulted in a 22% risk
reduction of death compared with PLD alone, resulting in a 4.3
month improvement in median values (HR ¼ 0.78; 95% CI 0.62–0.98;
P ¼ 0.032; median OS 28.4 vs. 24.1 months). The best-fitting survival
model as measured by the C-statistic, adjusted for key prognostic
factors including PFI, demonstrated a significant increase in OS for
trabectedin plus PLD patients in the entire trial population (HR ¼
0.82; 95% CI 0.69–0.98; P ¼ 0.029; median OS 22.2 vs. 18.9 months),
which could potentially improve the cost-effectiveness of trabec-
tedin plus PLD in the platinum-sensitive stratum [10].
The objective of this study was to investigate the cost-
effectiveness of trabectedin plus PLD compared with PLD alone
for patients with relapsed platinum-sensitive ovarian cancer who
are not expected to benefit from retreatment with platinum-based
therapies based on the final survival data from the OVA-301 trial.Methods
A decision-analytic model was constructed in Microsoft Excel to
estimate the costs and QALYs of a hypothetical cohort of patients
with relapsed platinum-sensitive ovarian cancer from the UK
Fig. 2 – Schematic of model structure.
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The model time horizon should be sufficiently long to capture the
differences in costs and outcomes between treatments. There-
fore, a lifetime horizon was chosen because patients accumulate
differential costs and QALYs until death. The choice of model was
based on the modeling approach taken by the technology assess-
ment group during the NICE Multiple Technology Appraisal
(TA91) for ovarian cancer treatments [8,13], which permitted the
estimation of mean PFS and OS to characterize the clinical
benefits of each treatment, facilitating the calculation of QALYs
without overcomplicating the treatment paradigm.
Internal validation of the model was conducted independ-
ently by health economists and clinical specialists. External
validation was also considered by comparing PFS and OS from
the model with observations from the OVA-301 trial.
Comparators
The model compares trabectedin plus PLD with PLD alone on the
basis of head-to-head data from the OVA-301 trial. Although
platinum-based regimens are recommended as the first choice
treatment for second-line chemotherapy in patients with
platinum-sensitive disease in the UK, PLD is recommended in two
important subgroups of this population: patients with partially
platinum-sensitive disease and patients with platinum-sensitive
disease who are allergic to platinum-based compounds [8]. In
addition, during the technology appraisal of trabectedin, NICE
acknowledged PLD as a relevant comparator in patients with
platinum-sensitive disease in whom platinum-based regimens
would be unsuitable [12]. Therefore, results from this analysis
should only be interpreted for platinum-sensitive patients in whom
PLD would be considered an appropriate treatment option. Because
the identified subgroups were not prespecified prior to random-
ization of the OVA-301 trial, it has been acknowledged that post hoc
subgroup analyses may be underpowered and hence the best
estimates of treatment effect within these subgroups would be that
of the entire platinum-sensitive population [12].
A systematic review and critical appraisal of studies investigat-
ing interventions in ovarian cancer did not identify any evidence
that could be used in an indirect comparison of platinum-based
therapies. Therefore, because of a lack of trials that linked into the
network of evidence that included trabectedin plus PLD, it was not
possible to perform an indirect comparison with platinum-based
compounds. The review did identify potential indirect comparisons
between trabectedin plus PLD and topotecan or paclitaxel mono-
therapy; however, clinical experts believed that there would never
be a choice between trabectedin and PLD and these treatments.
Details of the review and network of evidence can be found in the
Evidence Review Group (ERG) report [14].
The hypothetical cohort received treatment with either tra-
bectedin plus PLD or PLD alone. The method of administration for
trabectedin and PLD was central line infusion and peripheral
intravenous infusion, respectively. Over the lifetime horizon, the
mean total dose per patient assuming wastage was based on the
mean results recorded for OVA-301 platinum-sensitive patients,
and a mean body surface area of 1.7 m2: Trabectedin was administered as three 0.25-mg vials and one
1-mg vial for 6.9 months PLD was administered as one 50-mg vial with the combination
treatment for 6.9 months and two 50-mg vials when taken
alone for 5.7 months
Model Structure
The model structure (Fig. 2) was based on the NICE Multiple
Technology Appraisal (TA91) and is characterized by three healthstates: stable disease, progressive disease, and dead [13]. Costs
and QALYs for each treatment were accumulated on the basis of
the mean time spent in the stable and progressive disease states.
Patients began in the stable state and transitioned to the
progressive state after the mean PFS period; thereafter, patients
transitioned to dead after the mean (OS – PFS) period. Therefore,
OS was calculated in relation to two distinct periods: the
progression-free period (time in the stable state or PFS) and the
time from progression to death (time in the progressive state
estimated as the difference between OS and PFS). The choice of
modeling stable and progressive disease states was to capture the
differences in costs and quality of life between the states.
Effectiveness
The effectiveness values of trabectedin plus PLD and PLD alone
were calculated as the treatment-specific mean PFS and OS based
on OVA-301, the only randomized controlled trial providing direct
evidence of trabectedin plus PLD and PLD alone in patients with
platinum-sensitive ovarian cancer. Eligible women were 18 years or
older with histologically confirmed epithelial ovarian, fallopian
tube, or primary peritoneal carcinoma. They had received only
one prior platinum-based chemotherapy regimen, and experienced
recurrence or progression. Patients stratified by the ECOG perform-
ance score (0–1 or 2) and platinum sensitivity (sensitive: PFIZ 6
months, or resistant: PFIo 6 months) were randomly assigned to
receive an intravenous infusion of PLD 30 mg/m2 followed by a 3-
hour infusion of trabectedin 1.1 mg/m2 every 3 weeks (n ¼ 337) or
PLD 50 mg/m2 every 4 weeks (n ¼ 335). The primary end point was
PFS assessed by independent radiology review, and OS based on the
final analysis was a secondary end point. Further details of the
OVA-301 trial have been published elsewhere [9,10].
Statistical Analysis
The methodology used to calculate mean PFS and OS was based
on the methods applied by the NICE ERG when trabectedin plus
PLD was appraised during 2010–2011 [14]. The statistical analysis
performed by the ERG, however, was based on interim results of
the OVA-301 (419 deaths) and analyzed PFI as a categorical
covariate (platinum-sensitive vs. platinum-resistant). Hence, no
adjustment for PFI was made in the analysis of platinum-
sensitive patients. In this evaluation, the statistical analysis is
presented on the basis of final survival results (522 deaths) and
importantly, because of the observed continuous PFI imbalance,
PFI is analyzed as a continuous covariate.
In line with the marketing authorization of trabectedin plus
PLD, only the data for patients with platinum-sensitive disease
were included in the analysis; data for platinum-resistant patients
were excluded. To align with ERG recommendations, patients with
no measurable disease at baseline were excluded when analyzing
PFS [14]. Patients who discontinued the treatment were included in
the analysis because the study was intention to treat. However,
patients lost to follow-up were censored.
Table 1 – Baseline covariates by treatment arm.
Treatment arm Mean PFI ECOG 2 (%) CA-125Z2x ULN (%) Mean age (y) White (%)
Trabectedin plus PLD 14.3 31 76 57.0 80
PLD 19.0 41 85 59.0 78
Treatment arm Asian (%) Black (%) Other (%) Lung/liver involvement (%) Prior taxane (%)
Trabectedin plus PLD 18 1 1 41 76
PLD 21 1 0 39 77
CA-125, cancer antigen 125; ECOG, Eastern Cooperative Oncology Group; PFI, platinum free interval; PLD, pegylated liposomal doxorubicin;
ULN, upper limit of normal.
Table 3 – Final distributions adjusting for log(PFI), CA-125, and ECOG performance score.
Treatment Outcome Model Observations AIC BIC Mean
Trabectedin plus PLD PFS Weibull 213 451.2 468.0 11.26
PLD alone PFS Weibull 193 380.9 397.3 8.25
Trabectedin plus PLD OS Log-logistic 216 508.0 524.9 44.69
PLD alone OS Log-logistic 202 472.7 489.2 34.97
AIC, Akaike information criterion; BIC, Bayesian information criterion; CA-125, cancer antigen 125; ECOG, Eastern Cooperative Oncology
Group; OS, overall survival; PFI, platinum-free interval; PFS, progression-free survival; PLD, pegylated liposomal doxorubicin.
Table 2 – Five distributions fit to OS and PFS by treatment arm adjusting for PFI, CA-125, and ECOG
performance score.
Model Observations AIC BIC Model Observations AIC BIC
Trabectedin plus PLD: Progression-free survival Trabectedin plus PLD: Overall survival
Exponential 213 463.9 477.4 Exponential 216 537.8 551.3
Weibull 213 454.1 470.9 Weibull 216 513.9 530.8
Gompertz 213 460.4 477.2 Gompertz 216 524.6 541.5
Log-logistic 213 454.2 471.0 Log-logistic 216 512.0 528.9
Log normal 213 457.7 474.5 Log normal 216 523.5 540.4
PLD: Progression-free survival PLD: Overall survival
Exponential 193 400.5 413.6 Exponential 202 502.2 515.5
Weibull 193 383.7 400.0 Weibull 202 480.3 496.8
Gompertz 193 386.6 402.9 Gompertz 202 490.0 506.5
Log-logistic 193 389.6 405.9 Log-logistic 202 475.3 491.8
Log normal 193 391.9 408.2 Log normal 202 483.1 499.7
AIC, Akaike information criterion; BIC, Bayesian information criterion; CA-125, cancer antigen 125; ECOG, Eastern Cooperative Oncology
Group; OS, overall survival; PFI, platinum-free interval; PFS, progression-free survival; PLD, pegylated liposomal doxorubicin.
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survival distributions (Exponential, Weibull, Gompertz, log-logis-
tic, and log normal) by treatment arm to the PFS and OS data
separately, adjusting for potential covariates, to extrapolate PFS
and OS over a lifetime horizon and obtain the mean PFS and OS
for each treatment.
Baseline covariates considered included age (as a continuous
variable); race (Caucasian, Black, Asian, or other); ECOG perform-
ance score (0/1 or 2); PFI (as a continuous variable); cancer
antigen 125 (CA-125) (o2 upper limit of normal or Z2 upper
limit of normal); liver or lung involvement (yes or no); and prior
taxane use (yes or no). An analysis of covariates by arm was
undertaken to identify any differences in baseline covariates
between arms (Table 1). The analysis found noticeable differ-
ences between the arms in three covariates; a 4.7-month (25%)
difference in PFI, a 10% difference in the proportion of patients
with ECOG performance score of 2, and a 9% difference in the
proportion of patients with CA-125 value of 2  upper limit of
normal or more. It is acknowledged that PFI, CA-125, and ECOG
performance score are all statistically significant predictors ofsurvival [14]. In particular, CA-125 remains the only well-defined,
validated tumor marker to have a significant impact on the
clinical management of ovarian cancer [15,16]; it has been shown
that a decrease in CA-125 can be predictive of radiological
response [17]. Therefore, to ensure no biases were introduced
by these differences, we adjusted the survival distributions by
PFI, CA-125, and ECOG performance score; 12 patients were
excluded following adjustment because of missing CA-125 data.
A similar process was undertaken by the ERG during initial
assessment, but only CA-125 was adjusted for because imbal-
ances in continuous PFI were not reported during the interim
analysis [14].
Goodness-of-fit criteria based on Akaike information crite-
rion (AIC) and Bayesian information criterion (BIC) of each
survival distribution were used to select the preferred distri-
bution for PFS and OS by treatment arm. The lower the AIC
and BIC, the better fit the distribution is to the observed data.
In addition, the survival distributions and Kaplan-Meier plots
were analyzed to ensure that the survival distributions closely
predicted the observed PFS and OS events. Table 2 summarizes
Fig. 3 – Progression-free survival Kaplan-Meier (KM) plot with final Weibull models. PLD, pegylated liposomal doxorubicin.
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for PFI, CA-125, and ECOG performance score: The Weibull distribution was chosen for PFS for both trabec-
tedin plus PLD and PLD alone The log-logistic distribution was chosen for OS for both
trabectedin plus PLD and PLD alone
Finally, we examined the functional form of the continuous
variables considered for the chosen distributions, namely, PFI. By
using linear, logarithm, and exponential forms, we found that the
logarithm was a significantly better fit compared with the linear
and exponential; AIC was reduced by approximately 3 or more for
the four selected distributions (Table 3). Therefore, mean PFS and
OS for trabectedin plus PLD and PLD alone were based on Weibull
and log-logistic distributions, which adjusted for log (PFI), ECOG
performance score, and CA-125. Based on the Weibull distributions,
the mean PFS for trabectedin plus PLD and PLD alone was 11.26 and
8.25 months, respectively. Based on the log-logistic distributions,
the mean OS for trabectedin plus PLD and PLD alone was 44.69 and
34.97 months, respectively. Figures 3 and 4 show the survival
distributions and Kaplan-Meier plots for PFS and OS; both figures
confirm that the final distributions fit the data reasonably well.
Costs
The following direct costs were considered for a 2011 price year:
drug acquisition costs, administration costs, medical management
costs, and costs of treating adverse events (Table 4). All drug
acquisition costs were taken from the British National Formulary
[18]. Total drug costs were calculated by multiplying the monthly
drug cost by the mean duration of treatment, as observed in OVA-
301. The cost of an administration for each treatment was based on
UK Health Resource Group codes [19]. The total cost of adminis-
tration was calculated by multiplying the cost of one administration
by the mean duration of treatment. In addition, the use of a central
line for trabectedin administration was costed as a one-off cost [19].
Medical management costs were dependent on whether a patient
was stable or progressive (Fig. 2). During the progression-free period,
it was assumed that patients attended one outpatient visit permonth and one computed tomography scan every 2 months, costs
of which were based on appropriate Health Resource Group codes
[19]. During the time from progression to death, it was assumed that
patients received palliative care; a 2001 cost was collected in
palliative care study for patients with advanced cancer [20] and
the annual cost was inflated to 2011 by using the Hospital and
Community Health Services index inflation indices from the Per-
sonal Social Services Research Unit [21]. The cost of treatment-
related adverse events, as observed in OVA-301, was collected and
incorporated into the model (Table 4). Adverse events were consid-
ered for costing purposes within the health economic model if they
were grade III or IV, or occurred at an incidence equal or greater than
10% in either of the arms of the trial and were considered to have a
significant cost associated with them. Appropriate Health Resource
Group codes were used to calculate the cost of treating the adverse
events. All costs were discounted assuming a 3.5% discount rate; the
exponential discounting method was used by taking into account
the amount of time spent in the stable and progressive states.
Utilities
The EuroQol five-dimensional questionnaire data collected in the
OVA-301 trial were used to estimate quality of life associated with
each state in the model. Quality of life associated with a state is
measured by determining the utility, a cardinal ranking scale
defined by the following: Utility ¼ 1: perfect health
 Utility ¼ 0: death or equivalent
 Utility o 0: worse than deathBased on the EuroQol five-dimensional questionnaire data
measured in the OVA-301 population, the mean utility while in
the stable and progressive states was 0.718 and 0.649, respectively
[14]. Utility was assumed to be constant over time as repeated
measurements from the study found no systematic change with
time. The utility for each state was multiplied by the mean time
spent in each state to obtain QALYs. All outcomes were dis-
counted assuming a 3.5% discount rate; similarly to the discount-
ing of costs, the exponential discounting method was used.
Fig. 4 – Overall survival Kaplan-Meier (KM) plot with final log-logistic models. PLD, pegylated liposomal doxorubicin.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 5 0 7 – 5 1 6512Sensitivity Analysis
Uncertainty was addressed through deterministic sensitivity
analysis (DSA) and probabilistic sensitivity analysis (PSA). DSA
was performed by evaluating a number of scenarios: No adjustment for PFI in the survival distributions (i.e.,
considering platinum-sensitive and platinum-resistant as cat-
egorical covariates) Choosing alternative survival distributions for PFS and OS
with adjustment for log(PFI), ECOG performance score, and
CA-125 Considering an alternate method for adjusting for covariates
when selecting survival distributions. The method identified
and adjusted for covariates that were significant predictors of
outcome (OS or PFS) Using treatment-specific utilities to incorporate the effect on
quality of life due to treatment-specific adverse events.
Utilities calculated for the stable and progressive states were
0.719 and 0.698 for trabectedin plus PLD and 0.732 and 0.709
for PLD alone, respectively. This was not considered in the
base case because utilities were assumed constant over time
and adverse events are typically resolved within a month.
In addition, PSAwas performed on the basis of 1000 iterations,
sampling values from predefined distributions for all parameters
in the model. Results were presented as an ICER plane and cost-
effectiveness acceptability curve.Results
Base Case
The base-case results can be viewed in Table 5. Over a lifetime
horizon, the model estimated that trabectedin plus PLD increased
the mean PFS by 3.0 months and OS by 9.7 months compared
with PLD alone in the platinum-sensitive population. The addi-
tional cost and QALYs of trabectedin plus PLD was £18,476 and
0.49, respectively, resulting in an ICER of £38,026 per QALY.Sensitivity Analysis
The DSA found that the ICER increased substantially to £107,621
when PFI was considered as a categorical covariate (platinum-
sensitive vs. platinum-resistant) and not adjusted for within the
survival distributions (Table 6). Although the selected survival
distributions remained unchanged, the increase in the ICER was
primarily due to an increase in OS from 34.97 to 41.44 in the PLD
arm, which was also associated with a significant increase in AIC
from 472.7 to 504.7. The significant increases in AIC across the
survival distributions suggested that not adjusting for PFI pro-
duced significantly worse fitting survival distributions. When
considering alternative survival distributions for PFS and OS,
the second best fitting distributions based on AIC and BIC were
chosen; these were the Gompertz and Weibull, respectively
(Table 6). The ICER increased to more than £50,000 when the
more conservative (but worse fitting) Weibull distribution was
used as opposed to the log-logistic. Goodness of fit was margin-
ally worse when considering the Weibull (AIC ¼ 508.1) compared
with the log-logistic (AIC ¼ 508.0) distribution for trabectedin plus
PLD, and significantly worse when considering the Weibull (AIC ¼
478.5) compared with the log-logistic (AIC ¼ 472.7) distribution for
PLD alone. When using the alternative method for adjusting for
covariates and selecting survival distributions, the ICER margin-
ally reduced to £37,242. The alternative method found that PFI
and race (Black) were significant predictors of PFS while PFI, CA-
125, ECOG performance score, liver/lung involvement, and age
were significant predictors of OS. Therefore, the five survival
distributions adjusted for the respective covariates for PFS and
OS. As before, the Weibull and log-logistic distributions were the
best fit for PFS and OS in both arms, respectively, and log(PFI)
improved the fit of the distributions. Finally, using treatment-
specific utilities and prolonging any disutility experienced due to
treatment-related adverse events to that of a lifetime marginally
increased the ICER to £38,673.
The results of the PSA showed that the mean ICER based on
1000 stochastic simulations was £39,867. The ICER plane showed
that the majority of simulations were in the northwest quadrant
where trabectedin plus PLD was more effective and more costly
than PLD (Fig. 5). The cost-effectiveness acceptability curve
Table 4 – Costs inputs.
Cost Mean Reference
Drug acquisition costs (£)
Trabectedin 1366 per 1-mg vial; 363 per 0.25-mg vial [18]
PLD 712.49 per 50-mg vial; 360.23 per 20-mg vial [18]
Administration costs (£)
Trabectedin 334 per administration [19] (HRG: SB14Z)
PLD 208 per administration [19] (HRG: SB12Z)
Trabectedin one-off central line 451 [19] (HRG: QZ14B)
Medical management costs (£)
Outpatient visits 118 per visit [19] (HRG: 503)
Computed tomography scans 133 per visit [19] (HRG: RA12Z)
Palliative care (inflated) 6157 per year [20,21]
Cost of treating adverse events
Grade III anemia 481 [19] (HRG: SA13A)
Grade IV anemia 481 [19] (HRG: SA13A)
Grade III diarrhea 118 [19] (HRG: 503)
Grade IV diarrhea 2006 [19] (HRG: FZ47B)
Grade III nausea/vomiting 118 [19] (HRG: 503)
Grade IV nausea/vomiting 2822 [19] (HRG: FZ43A)
Grade III febrile neutropenia 2149 [19] (HRG: SA01F)
Grade IV febrile neutropenia 2149 [19] (HRG: SA01F)
Grade III neutropenic infection 2149 [19] (HRG: SA01F)
Grade IV neutropenic infection 2149 [19] (HRG: SA01F)
Grade III neutropenic sepsis 2149 [19] (HRG: SA01F)
Grade IV neutropenic sepsis 2149 [19] (HRG: SA01F)
Grade III neutropenia 118 [19] (HRG: 503)
Grade IV neutropenia 2149 [19] (HRG: SA01F)
Grade III PPE 118 [19] (HRG: 503)
Grade IV PPE 2728 [19] (HRG: JD05C)
Grade III thrombocytopenia 481 [19] (HRG: SA13Z)
Grade IV thrombocytopenia 481 [19] (HRG: SA13Z)
Grade III stomatitis 118 [19] (HRG: 503)
Grade IV stomatitis 1641 [19] (HRG: CZ23Y)
HRG, Health Resource Group; PLD, pegylated liposomal doxorubicin; PPE, palmar-plantar erythrodysesthesia.
Table 5 – Base-case results.
Treatment Total cost (£) Total QALYs gained ICER
Trabectedin plus PLD 41,880 2.33 –
PLD 23,404 1.85 –
Incremental 18,476 0.49 £38,026
ICER, incremental cost-effectiveness ratio; PLD, pegylated liposomal doxorubicin; QALYs, quality-adjusted life-years.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 5 0 7 – 5 1 6 513showed that at ICER thresholds of £20,000, £30,000, and £50,000,
the probability that trabectedin plus PLD was cost-effective
compared with PLD alone was 2%, 33%, and 72%, respectively
(Fig. 6).Discussion
The cost-effectiveness analysis calculates an ICER of £38,026 per
QALY gained for trabectedin plus PLD compared with PLD alone
for the treatment of patients with platinum-sensitive ovarian
cancer. In the UK, end-of-life criteria are considered for treat-
ments that can provide an extension to life in patients with a
short life expectancy [22]. The implication for treatments ful-
filling end-of-life criteria is that higher ICER thresholds are
applied to evaluate whether a treatment is cost-effective.
Although no formal threshold has been set for end-of-lifetreatments, the highest cost per QALY of such a treatment
recommended by NICE is £50,000 [23]. Previously, trabectedin
plus PLD was shown not to fulfill these criteria due to uncertainty
in the survival gain compared with PLD alone based on the
interim analysis of OS [12]. However, when considering the log-
logistic survival distributions based on the final analysis of OS,
trabectedin plus PLD demonstrated an OS gain of 9.7 months
compared with PLD alone. This is well above the 3-month gain
required for end-of-life criteria, and therefore, it appears that
trabectedin plus PLD has a stronger case for being considered as
an end-of-life treatment. Nevertheless, the authors acknowledge
that firm conclusions should be made by NICE alone.Strengths of the Analysis
First, the analysis is based on the final OS data from OVA-301, a
large (n ¼ 672), rigorously conducted randomized trial in patients
Table 6 – Sensitivity analysis with PFI adjustment and choosing different survival distributions.
Scenario Trabectedin plus
PLD (PFS)
PLD alone (PFS) Trabectedin plus PLD
(OS)
PLD alone (OS) ICER (£)
Base case Weibull AIC ¼ 451.2 Weibull AIC ¼ 380.9 Log-logistic AIC ¼ 508.0 Log-logistic AIC ¼ 472.7 38,026
No PFI adjustment Weibull AIC ¼ 456.3 Weibull AIC ¼ 385.8 Log-logistic AIC ¼ 514.3 Log-logistic AIC ¼ 504.7 107,621
Distribution 1 Gompertz AIC ¼ 457.7 Gompertz AIC ¼ 384.0 Log-logistic AIC ¼ 508.0 Log-logistic AIC ¼ 472.7 38,048
Distribution 2 Weibull AIC ¼ 456.3 Weibull AIC ¼ 380.9 Weibull AIC ¼ 508.1 Weibull AIC ¼ 478.5 51,090
Distribution 3 Gompertz AIC ¼ 457.7 Gompertz AIC ¼ 384.0 Weibull AIC ¼ 508.1 Weibull AIC ¼ 478.5 51,123
AIC, Akaike information criterion; ICER, incremental cost-effectiveness ratio; OS, overall survival; PFI, platinum-free interval; PFS, progression-
free survival; PLD, pegylated liposomal doxorubicin.
Fig. 5 – Incremental cost-effectiveness ratio plane. QALYs, quality-adjusted life-years.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 5 0 7 – 5 1 6514with relapsed ovarian cancer. Quality-of-life data with the Euro-
Qol five-dimensional questionnaire were collected during the
trial. The trial met its primary end point in the overall population,
with statistically significant reduction in the risk of disease
progression or death. Second, the analysis presented here is
based on the final survival data (522 events) for patients with
platinum-sensitive ovarian cancer and provides an update to a
previous cost-effectiveness analysis, carried out as part of a
health technology assessment in the UK. Third, it is recognized
that the statistical likelihood of an ovarian cancer patient
obtaining clinically relevant benefit from retreatment with a
platinum regimen is a continuum, with increasing response rates
associated with longer PFI periods [3]. For example, with a PFI of 6
to 12 months, 20% to 30% of the patients are likely to achieve an
objective response to reintroduction of platinum-based therapy,
whereas with an interval of 18 to 24 months, that rate may
increase to 60% to 70% [5]. PFI is a relevant prognostic factor in
patients with relapsed ovarian cancer and has been acknowl-
edged as a significant predictor of both death and progression
[3,14]; this was also demonstrated in post hoc analyses conducted
in the OVA-301 trial, which showed that patients stratified by less
than 6 months, 6 to 12 months, and more than 12 months had
significant differences in OS [10]. Importantly, PFI is a continuous
variable and because clinical trial design prevents stratification of
populations by continuous variables, it has been customary
in ovarian cancer trials to divide PFI into two categories,platinum-resistant (PFI o 6 months) and platinum-sensitive
(PFI Z 6 months). Thus, at the time the OVA-301 trial was
designed, the stratification of the patient population followed
this criterion and because of this convention, only platinum-
sensitive or platinum-resistant status was reported during the
NICE submission. The stratification, however, did not ensure
balance with respect to continuous PFI between the treatment
arms at baseline when analyzing platinum-sensitive patients and
the final OS analysis demonstrated a significant imbalance;
patients in the PLD-alone arm had a significantly longer mean
PFI (13.3 months) than did patients in the combination arm (10.6
months) (P ¼ 0.009) [10] and for platinum-sensitive patients an
even larger difference in mean PFI was observed: 19.0 months in
the PLD arm versus 14.3 months in the trabectedin plus PLD arm
(P ¼ 0.002). Therefore, accounting for the imbalance in continu-
ous PFI and other prognostic factors strengthens the analysis.
Fourth, uncertainty was explored through DSA and PSA; results
were most sensitive to adjusting for continuous PFI and choice of
survival distributions. With no adjustment for PFI, the ICER
increased substantially to £107,621; however, the goodness of fit
for each of the survival distributions was significantly worse.
Considering Weibull distributions in the extrapolation of OS
resulted in ICERs above the highest cost per QALY accepted by
NICE for end-of-life treatments (£50,000 per QALY). The goodness
of fit for both Weibull distributions, however, was worse when
compared with the log-logistic distributions considered in the
Fig. 6 – Cost-effectiveness acceptability curve. PLD, pegylated liposomal doxorubicin.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 5 0 7 – 5 1 6 515base case. Finally, the model captures the effects of single and
doublet chemotherapy toxicities by accounting for adverse event
costs and health-related quality of life as observed in OVA-301.
Limitations of the Analysis
The cost-effectiveness analysis does not provide a comparison
against platinum-based chemotherapy agents, which are the
standard treatment for women with relapsed platinum-
sensitive ovarian cancer. No direct head-to-head trials compared
trabectedin plus PLD with platinum-based therapy, and results of
a systematic review showed that the network of evidence did not
provide sufficient pairwise comparisons from which a robust
indirect comparison could be performed [14].
Although platinum-based combinations are the mainstay of
treatment for women with platinum-sensitive relapsed ovarian
cancer, a relevant proportion of patients are not eligible because
of expected lack of benefit or toxicities. First, the probability of
response to platinum decreases with the interval from last
platinum [5,24] and there is a lack of consensus for the optimal
treatment in patients with partially platinum-sensitive disease
(PFI 6–12 months) who may benefit from non–platinum-based
therapies. This is highlighted by the fact that PLD has been
recommended in the UK as a treatment option for women with
ovarian cancer who have partially platinum-sensitive disease and
women with platinum-sensitive disease who are allergic to
platinum-based compounds [8]. Among the 214 patients with
partially platinum-sensitive disease in the OVA-301 trial, the
effect of treatment was even more prominent with a 36% decrease
in the risk of death and a 6-month improvement in median OS
with trabectedin plus PLD compared with PLD alone (HR ¼ 0.64;
95% CI 0.47–0.86; P ¼ 0.003; median OS 22.4 vs. 16.4 months) [2].
Second, for patients with severe platinum hypersensitivity reac-
tions, the risk may outweigh the benefits [5]. Platinum hyper-
sensitivity develops more frequently in the second-line setting,
reportedly exceeding 20% in the relapse setting and occurring in
up to a third of all patients [25,26]. Fifty percent of these patients
do not receive further carboplatin treatment [27–29] and although
cisplatin is an alternative, it is associated with significant tox-
icities, such as renal failure or ototoxicity [5]. Persistentneurological toxicity is also a significant factor precluding the
use of carboplatin/paclitaxel combinations [30]. Therefore, there
are circumstances when particular subgroups of platinum-
sensitive patients would benefit more from nonplatinum agents
such as trabectedin plus PLD. Although OVA-301 was not powered
for analysis of platinum-sensitive subgroups, the data for the
entire platinum-sensitive population have been viewed as the
best estimate for cost-effectiveness analyses in these subgroups
[12]. Hence, this analysis can be considered representative of
relevant platinum-sensitive subgroups in which nonplatinum
regimens are appropriate. OVA-301 enrolled 430 patients with
platinum-sensitive disease whowere ineligible or not willing to be
retreated with platinum-based chemotherapy or were not
expected to benefit from it. This fact further supports the need
for a nonplatinum-based combination therapy in this clinical
setting and indicates that trabectedin plus PLD can be a valid
treatment option for those patients who are not expected to
benefit from retreatment with platinum-based therapies.
As with all modeling studies that extrapolate outcome data
past the trial end point, it is difficult to interpret the precise
outcome of OS over a lifetime. However, survival distributions fit to
the trial data were used, which adjusted for covariates where
treatment arm imbalances were observed and survival distribu-
tions were selected on the basis of goodness-of-fit criteria (AIC and
BIC). In addition, analysis of the survival distributions with Kaplan-
Meier plots confirmed the goodness of fit. We acknowledge that
the choice of distribution and adjustment for covariates can be
open to interpretation; for this reason, we tested the choice of
survival distributions as well as the method for adjusting for
covariates in sensitivity analyses. These analyses highlighted that
results were particularly sensitive to the extrapolation of survival,
and alternative methods for fitting survival distributions or adjust-
ing for PFI significantly increased the ICER.
Further Research
The study was performed from the UK National Health Service
and Personal Social Services perspective and is therefore general-
izable only to this setting. Further research should be undertaken
to explore the impact on results if the perspective was broadened
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 5 0 7 – 5 1 6516to include indirect costs such as productivity losses and unpaid
carer time. In addition, clinical studies comparing trabectedin
and platinum combinations would be useful to determine opti-
mal treatment decision making for patients with platinum-
sensitive ovarian cancer. There is an ongoing study to compare
trabectedin plus PLD with paclitaxel plus carboplatin, results of
which are expected in the next few years. It is hoped that this will
breach the gap in understanding the relative clinical effective-
ness between platinum and nonplatinum therapies as second-
line treatment for ovarian cancer.Conclusions
Analysis based on the final survival data showed a significant
improvement in the OS and incremental cost per QALY originally
calculated and submitted to NICE based on interim analysis. It is
unclear whether trabectedin plus PLD can be considered as a
cost-effective alternative for patients with platinum-sensitive
disease who are not expected to benefit from retreatment with
platinum-based therapies. The ICER of £38,026 per QALY could be
considered cost-effective in the UK setting despite it being above
the traditional NICE threshold values of £20,000 to £30,000 per
QALY [31] as a consequence of trabectedin plus PLD being a
candidate for end-of-life criteria [22]. The authors, however,
acknowledge that only NICE is in a position to determine whether
trabectedin plus PLD now fulfills this criteria.Acknowledgments
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